We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 66

Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


Gene Patents Remain Valid in Canada
  • Bereskin & Parr LLP
  • Canada
  • March 10 2016

The case involving a Children’s Hospital of Eastern Ontario (“CHEO”) challenge to an isolated gene patent has settled. For background on the case and


Supreme Court of Canada denies leave to appeal in PM(NOC) judicial comity case
  • Bereskin & Parr LLP
  • Canada
  • May 9 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Allergan Inc. et al ats. Apotex Inc


Supreme Court Promises to Review Contentious Patent Matter
  • Bereskin & Parr LLP
  • Canada
  • March 14 2016

At long last, the Supreme Court of Canada will hear a case involving the promise of the patent. The promise of the patent is a judge-made doctrine in


Biosimilar Approvals in the US and Canada - Sidestepping the 'Patent Dance'
  • Bereskin & Parr LLP
  • Canada, USA
  • January 12 2016

A passing moment of social awkwardness between a couple on a dance floor is nothing compared to the situation when the sidestepping is between two


Leave to Appeal to SCC: AstraZeneca Canada Inc et al v Apotex Inc et al (FCCA)
  • Bereskin & Parr LLP
  • Canada
  • March 10 2016

On March 10, 2016, the Supreme Court of Canada granted AstraZeneca Canada Inc.'s ("AstraZeneca") application for leave to appeal from the decision of


What to expect when you are expecting to launch a drug in Canada regulatory overview
  • Bereskin & Parr LLP
  • Canada
  • March 2 2015

This article provides a brief overview of key regulatory issues to be aware of when marketing a drug in Canada. Price Regulation and Reimbursement


Expert opinion as to what “one would expect” is speculation, not evidence
  • Bereskin & Parr LLP
  • Canada
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice


Eli Lilly files notice of arbitration in $500m NAFTA dispute against Canada
  • Bereskin & Parr LLP
  • Canada, Global
  • September 23 2013

In the past 10 years, there has been a significant increase in the number of Canadian pharmaceutical patents, which have been invalidated by the


USPTO issues new subject matter guidance post-Myriad and Prometheus
  • Bereskin & Parr LLP
  • Canada
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately